Florian Brand - 14 Mar 2024 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Role
Co-Founder & Chief Executive Officer
Signature
/s/ Ryan Barrett , Attorney-in-fact
Issuer symbol
ATAI
Transactions as of
14 Mar 2024
Net transactions value
$0
Form type
4
Filing time
15 Mar 2024, 20:16:13 UTC
Previous filing
20 Nov 2023
Next filing
20 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATAI Common Shares Options Exercise +350,000 +269% 480,000 14 Mar 2024 Direct F1
holding ATAI Common Shares 2,333 14 Mar 2024 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATAI Restricted Stock Unit Options Exercise $0 -350,000 -50% $0.000000 350,000 14 Mar 2024 Common Shares 350,000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date.

Remarks:

Co-Founder & Chief Executive Officer